Research progress and prospect of Siglec in innate immune cells in tumor
Immunotherapy brings hope to those patients suffering from malignant tumor. However, common immunotherapy targets, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed death ligand-1 (PD-L1), have low positive expression rate in patients, and only a few patients can benefit fr...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Editorial Office of China Oncology
2022-12-01
|
| Series: | Zhongguo aizheng zazhi |
| Assuntos: | |
| Acceso en liña: | http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2022.12.012 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|